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Abstract
The approvals of nintedanib and pirfenidone changed the treatment paradigm in idiopathic pulmonary fibrosis
(IPF), and increased our understanding of the underlying disease mechanisms. Nonetheless, many challenges and
unmet needs remain in the management of patients with IPF and other progressive fibrosing interstitial lung diseases.
This review describes how the nintedanib clinical programme has helped to address some of these challenges. Data
from this programme have informed changes to the IPF diagnostic guidelines, the timing of treatment initiation, and
the assessment of disease progression. The use of nintedanib to treat patients with advanced lung function
impairment, concomitant emphysema, patients awaiting lung transplantation and patients with IPF and lung cancer is
discussed. The long-term use of nintedanib and an up-to-date summary of nintedanib in clinical practice are discussed.
Directions for future research, namely emerging therapeutic options, precision medicine and other progressive
fibrosing interstitial lung diseases, are described.
Further developments in these areas should continue to improve patient outcomes.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive interstitial lung disease (ILD) of unknown cause in
which patients experience worsening lung function
resulting from progressive fibrosis. IPF is associated with
high rates of morbidity and mortality [1]. Two pharma-
cological therapies (nintedanib and pirfenidone) have
been shown to slow decline in lung function in patients
with IPF [1–5]. The United States Food and Drug Ad-
ministration and European Medicines Agency approvals
of nintedanib and pirfenidone changed the treatment
paradigm in IPF and increased understanding of the
underlying disease mechanisms [5]. However, these ap-
provals raised new questions in the management of ILD,
and prior unmet needs remain to be addressed. Such
needs can be observed in the following areas: diagnosis;
timing of treatment initiation; assessment of treatment
response and disease progression; treatment of special
patient populations; long-term treatment; and manage-
ment of other forms of progressive fibrosing ILD (Fig.
1). This review will discuss these challenges in the con-
text of data from the nintedanib clinical programme
(Phase II, III and IV clinical trials) and from routine clin-
ical practice in real-world settings (observational cohorts
including registries).
Diagnosis
In the 2011 ATS/ERS/JRS/ALAT guidelines for IPF diagno-
sis and treatment, the diagnosis of IPF required exclusion
of other potential causes of pulmonary fibrosis, and identifi-
cation of a usual interstitial pneumonia (UIP) pattern by
high-resolution computed tomography (HRCT). If a UIP
pattern was not clearly identified (“possible” or “inconsist-
ent with UIP”) by HRCT, confirmation of diagnosis via sur-
gical lung biopsy (SLB) was recommended [14]. SLB is
associated with an elevated risk of acute exacerbation,
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pneumothorax and mortality, and may therefore be in-
appropriate for some patients [15–18].
Reported rates of SLB usage in clinical practice vary.
Of patients (N = 417) in the Australian IPF registry diag-
nosed with IPF, 15% underwent SLB, but 16.5% had
radiological features inconsistent with UIP and did not
undergo SLB to confirm their diagnosis [19]. In a study
of US claims data for patients over 65 years of age with
a diagnosis code for IPF, 2518 patients had claims for
diagnostic tests for IPF, of which 2.3% had claims for
SLB [20]. SLB was used in 26.5% of patients with IPF in
the National IPF Registry in Spain, and in 34.1% of
patients in the INSIGHTS-IPF registry in Germany [21,
22]. Data from a Europe-wide registry showed that SLB
was used in 32% of patients in 2009, but only in 8% of
patients in 2016, a decrease attributed to increased use
of transbronchial cryobiopsy (cTBB) [23].
An analysis of computed tomography scans and lung
biopsies from multiple centres and trials examined the
HRCT category of “possible UIP”, defined in the 2011
guidelines, and divided it into “probable UIP” and “inde-
terminate UIP” (Table 1). In a cohort analysis of pul-
monary fibrosis, patients with “probable UIP” by HRCT
were significantly more likely to have “probable” or “def-
inite UIP” by SLB than those with “indeterminate UIP”
by HRCT [24]. This suggests that patients with “prob-
able” and “indeterminate UIP” should not be grouped
together [24]. Furthermore, a post-hoc analysis of the
INPULSIS trials found that patients with a clinical diag-
nosis of IPF who had not undergone SLB, but who had
traction bronchiectasis without honeycombing by HRCT
(similar to patients with “probable UIP” categorized
above), had a similar disease course and response to nin-
tedanib as those with honeycombing by HRCT or UIP
confirmed by SLB [25]. Altogether, these data suggest
that there exists a group of patients within the radio-
logical “possible UIP” group, recommended for SLB
according to the 2011 guidelines, whose SLB is likely to
Fig. 1 Ongoing challenges and unmet needs in the management of pulmonary fibrosis, and timeline of the nintedanib clinical programme to
date. Except where noted, trial duration is depicted as time from enrolment of the first participant until the last visit of the last participant. a, trial
of nintedanib versus placebo, shown as time from January 2013 until the last visit of the last participant [2]; b, trial of open-label nintedanib in
patients who completed INPULSIS, shown as time from January 2013 until completion of data collection for the primary endpoint analysis [6]; c,
trial of nintedanib versus placebo, to examine the effects of nintedanib on quantitative lung fibrosis score [7]; d, trial of add-on pirfenidone versus
placebo in patients already receiving nintedanib [8]; e, trial of nintedanib versus placebo in patients with systemic sclerosis-associated interstitial
lung disease [9]; f, trial to examine possible pharmacokinetic interactions between nintedanib and pirfenidone [10]; g, trial of sildenafil and
nintedanib versus nintedanib alone in patients with advanced lung function impairment [11]; h, trial of nintedanib versus placebo, to examine the
effects of nintedanib on concentrations of blood biomarkers for idiopathic pulmonary fibrosis [12]; i, trial of nintedanib versus placebo in patients
with progressive fibrosing interstitial lung disease [13]
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confirm a UIP pattern and thus a diagnosis of IPF, and
who experience similar disease course and response to
treatment as patients with confirmed diagnoses of IPF.
These studies, and others, led to the definition of a
“probable UIP” category in the Fleischner Society White
Paper and in the updated ATS/ERS/JRS/ALAT diagnosis
guidelines, both published in 2018. The 2018 guidelines
include a conditional recommendation for SLB in pa-
tients with “probable UIP;” the Fleischner Society White
Paper discusses that SLB may be unnecessary in these
patients, depending on clinical context [26–28].
The 2018 ATS/ERS/JRS/ALAT guidelines note that,
for patients with substantial physiological impairment or
comorbidities, SLB may have an unfavourable benefit/
risk ratio [27]. cTBB is potentially associated with less
morbidity and mortality than SLB, and may be more ap-
propriate than SLB for some patients in experienced
centres [26, 27, 29, 30]. A real-world study in patients
(N = 109) with ILD found no instances of mortality or
acute exacerbation within 90 days following cTBB, and
that 73.4% of the histological samples obtained had clear
diagnostic patterns [31]. A multicentre study of patients
(N = 65) with ILD in Australia who each underwent
both cTBB and SLB found that the histopathology was
consistent in 70.8% of cases. Multidisciplinary diagnosis
using samples obtained via cTBB or SLB agreed in 76.9%
of cases [32, 33]. However, a smaller study (N = 21) sug-
gested that, although 81% of cTBB samples had diagnos-
tic patterns, concordance between patterns in cTBB and
SLB samples may be low [34]. All three studies noted
that multidisciplinary discussions were necessary to ob-
tain diagnoses, and that histology was only part of the
evidence that contributed to IPF diagnosis [31, 34]. The
lack of a standardized procedure for cTBB and the pau-
city of evidence from large prospective trials means that
SLB remains the recommended procedure for most pa-
tients [26, 27].
In addition to imaging and histological tests, other
procedures can assist in the diagnosis of IPF. Analysis of
the composition of bronchoalveolar lavage fluid can help
in the diagnostic work-up of suspected IPF, specifically
to exclude alternative diagnoses. Serological testing, par-
ticularly for antinuclear antibodies, rheumatoid factor,
myositis panel and anticyclic citrullinated peptide levels
can specifically help in the differential diagnoses of ILDs
associated with connective tissue disorders [26, 27].
When to initiate treatment
The 2015 ATS/ERS/JRS/ALAT IPF treatment guidelines
contain conditional recommendations for nintedanib
and pirfenidone, but make no suggestions regarding tim-
ing of treatment initiation [35]. Real-world data suggest
that many patients are not treated with approved IPF
therapies immediately after diagnosis, despite the insidi-
ous, progressive nature of IPF. In a 2016 European pa-
tient chart survey, 53.6% of patients with IPF (N = 1783)
were not treated with nintedanib or pirfenidone [36]. A
retrospective review of Finnish (n = 158) and Swedish (n
= 174) patients with IPF found that, from 2014 to 2016,
45 (29.6%) Finnish and 111 (69.4%) Swedish patients
were prescribed nintedanib or pirfenidone [37]. Both
studies suggested that patients with higher forced vital
capacity (FVC) were less likely to receive antifibrotic
treatment [36, 37].
In a physician survey, approximately 50% of responders
cited reasons such as “stable” or “asymptomatic” disease,
Table 1 Summary of studies contributing to change in IPF diagnostic guidelines
Study author,
reference
Patient subgroup HRCT results SLB results Diagnosis by 2011
guidelines [14]
Notes
Cohort study involving 201 patients with pulmonary fibrosis who underwent lung biopsy within 1 year of chest CT scan




IPF Probable UIP* by HRCT was more
likely to have UIP confirmed by SLB
than indeterminate UIP* by HRCT
Indeterminate*18% Probable IPF




Post-hoc analysis of pooled data from the INPULSIS trials on 1061 patients with honeycombing and/or diagnosis of UIP by SLB
Raghu [25] Honeycombing or SLB Honeycombing Not specified IPF Disease progression & response to
nintedanib similar between groups
Not specified UIP
No honeycombing or SLB Features of possible UIP
and traction bronchiectasis,
no honeycombing
None available SLB required
*Definite UIP: peripheral and basilar predominant pulmonary fibrosis characterized by reticulation, honeycombing, and absence of findings to suggest another
specific diagnosis; probable UIP: peripheral and basilar predominant pulmonary fibrosis with reticulation, little/no honeycombing but with otherwise typical
features of UIP; indeterminate UIP: pulmonary fibrosis with imaging findings not sufficient to reach a definite, probable, or inconsistent with UIP diagnosis [24]
CT Computed tomography, HRCT High-resolution computed tomography, IPF Idiopathic pulmonary fibrosis, SLB Surgical lung biopsy, UIP Usual
interstitial pneumonia
Valenzuela et al. Respiratory Research            (2020) 21:7 Page 3 of 15
or “good” lung function, for waiting and observing pa-
tients before prescribing antifibrotic therapy, and 23%
thought that the adverse effects of treatment outweighed
the benefits in patients with preserved lung function [38].
Despite this, one observational study of patients in the UK
receiving nintedanib found that nintedanib discontinu-
ation rates were lowest in patients with higher FVC (≥
80%) [39].
Clinical data regarding the efficacy of nintedanib in pa-
tients with preserved FVC have been published. Subgroup
analyses of the INPULSIS trials have suggested that the
treatment effect of nintedanib is consistent across sub-
groups of disease severity, defined by FVC (> 70 or ≤ 70%
pred) and diffusing capacity for carbon monoxide (DLCO)
(> 40 or ≤ 40% pred) at baseline [40, 41]. Furthermore,
data show that the annual rate of lung function decline is
already pronounced in patients with more preserved lung
function and is similar between subgroups of patients with
FVC > 90% or FVC ≤ 90% at baseline who received pla-
cebo in the INPULSIS trials (224.6 and 223.6 mL/year,
respectively) [42]. In the recent INMARK trial, patients
with preserved FVC at baseline (mean 97.5%) receiving
nintedanib had a FVC change of +5.9 mL over 12 weeks,
whereas those receiving placebo had a change of −70.2
mL (P = 0.0008) over 12 weeks [43]. This aligned with
FVC changes observed over 12 weeks in patients with less
preserved FVC at baseline (mean 79.6%) in the INPULSIS
trials (Fig. 2) [2]. Taken together, these data suggest that
the rate of decline in FVC in patients with IPF is not
dependent on lung function impairment at baseline and is
clinically significant in patients with only limited func-
tional impairment.
The INMARK trial featured a 12-week randomized,
placebo-controlled period followed by a 40-week period
in which all patients received open-label nintedanib,
allowing for the assessment of a 12-week delay in treat-
ment initiation in patients with IPF [12]. Nintedanib
significantly reduced lung function decline in the initial
12-week period, and decline in FVC over the 40-week
period was similar to that observed in the nintedanib
arm of the INPULSIS trials. While the difference in FVC
decline after 52 weeks was not significant between
groups, the 12-week delay in treatment did not appear
to be fully compensated for over the 52-week trial
period. The proportions of patients with an absolute
FVC decline of ≥ 10% or death over 52 weeks were 25%
and 30% in the nintedanib and placebo groups, respect-
ively [43].
An analysis of data from clinical practice in Seoul,
South Korea indicated that low FVC was a risk factor for
acute exacerbations [44]. Post-hoc analyses of the
INPULSIS trials, and of the STEP-IPF trial of sildenafil
in patients with IPF, indicated that patients with lower
FVC are at greater risk of acute exacerbations than those
with preserved lung function [40, 45, 46]. In two such
analyses, nintedanib was associated with a lower risk of
acute exacerbations compared with placebo [45, 47].
Collectively, these data suggest that there is no signifi-
cant difference in the rate of lung function decline be-
tween patients with less impaired lung function and
those with more impaired lung function, and that the
treatment benefit of nintedanib is consistent irrespective
of lung function impairment at baseline. While the 2015
ATS/ERS/JRS/ALAT IPF treatment guidelines contain
no recommendations regarding timing of nintedanib or
pirfenidone initiation, several other guidelines for IPF do
[35]. German guidelines state that antifibrotic therapy
should be recommended to symptomatic patients at
time of diagnosis [48]. A Swiss position paper suggests
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Fig. 2 Rate of change in FVC over 12 weeks in the INMARK and INPULSIS trials. a [43],; b [2, 41], and data on file (Boehringer Ingelheim).
CI, confidence interval; FVC, forced vital capacity; SE, standard error
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is made, especially for patients who have experienced dis-
ease progression [49]. French guidelines recommend treat-
ing patients with IPF when the patient is diagnosed [50].
Assessing disease progression and treatment
response
FVC and DLCO are the pulmonary function tests (PFTs)
most frequently used to assess disease progression [51].
A post-hoc analysis of the INPULSIS trials found that
FVC decline over 24 weeks was not predictive of further
FVC decline in the following 24 weeks of treatment,
reflecting the heterogeneous course of IPF [52]. Simi-
larly, a ≥ 10% decline in FVC after 52 weeks in the
INPULSIS trials was not predictive of further FVC de-
cline in the first year of the INPULSIS-ON extension
study, although it was associated with higher mortality
than an FVC decline of < 10% [52]. Concordant data
were reported for the CAPACITY and ASCEND trials of
pirfenidone [53]. Most patients who continued treatment
with either drug did not have a decline in FVC of ≥ 10%,
irrespective of prior FVC declines, supporting the con-
tinuation of IPF therapy in patients who experience
declines in FVC [52, 53]. These results suggest that
changes in FVC do not necessarily reflect response to
antifibrotic treatment in individual patients.
Change in disease extent quantified by automated in-
terpretation of HRCT is being evaluated as a method of
assessing disease progression, but is not established in
clinical practice [51, 54]. A quantitative lung fibrosis
(QLF) score, derived from HRCT images, has been de-
veloped in patients with systemic sclerosis-associated
ILD (SSc-ILD) [55]. Change in QLF score correlates with
decline in FVC and DLCO in patients with IPF [56]. Data
from a prospective trial suggest that nintedanib treat-
ment is associated with a numerically smaller degree of
fibrotic change in lungs, by QLF score [7].
Automated interpretation of lung sounds is another
potential measure of disease progression in IPF. “Velcro”
crackles at baseline, measured by digital auscultation, are
associated with the presence of UIP in patients with ILD
[57]. A prospective pilot study found that longitudinal
changes in lung sounds were associated with clinical
deterioration in patients with IPF [58].
Change in St George's Respiratory Questionnaire
(SGRQ) scores is a validated measure of quality of life
(QoL) in IPF and was a secondary endpoint in the
INPULSIS trials [2]. The change in SGRQ total score from
baseline was significantly less (corresponding to less de-
terioration in QoL) in the nintedanib arm of INPULSIS-2
compared with placebo. However, there was no significant
difference in SGRQ score between the nintedanib and pla-
cebo arms of INPULSIS-1, nor was a significant difference
seen in the pooled analysis of the two trials [2]. The sug-
gested minimum important difference in SGRQ score,
based on data from the BUILD-1 trial of bosentan in IPF,
is between 5–8 points over 6 months [59]. However, an
analysis of data from the INPULSIS trials suggested that
changes of 4–11 points over 52 weeks were clinically
meaningful, although the authors state that further sensi-
tivity analyses are required [60].
The INMARK trial assessed serum levels of neoepi-
topes (degradation products of the extracellular collagen
matrix that accumulates in the lungs of patients with
pulmonary fibrosis) for their prognostic value in patients
with IPF [12]. Prior work found that the rates of change
of six neoepitopes, including C-reactive protein degraded
by matrix metalloproteinases 1 and 8 (CRPM), were
associated with disease progression and mortality [61].
The primary endpoint of INMARK was the rate of
change of serum CRPM after 12 weeks [12]. While there
was no significant difference in the rate of change of
CRPM between the nintedanib and placebo arms, rising
CRPM levels over 12 weeks (compared with falling or
stable CRPM levels) were associated with disease pro-
gression over 52 weeks. These results confirmed the
association of CRPM with disease progression, but did
not show that rates of change in neoepitope concentra-
tions were predictive of treatment response [12, 43].
Similarly, a post-hoc analysis of the CAPACITY and
ASCEND trials of pirfenidone found that C-C motif
ligand 18 was prognostic for disease progression, but
found no markers predictive of treatment response [62].
Treatment of special populations
The efficacy of nintedanib in slowing FVC decline was
first suggested by the results of the Phase II TOMOR-
ROW study, then confirmed in the two replicate Phase
III INPULSIS trials [2, 63]. However, further scrutiny is
required in some subgroups of patients because of their
exclusion from INPULSIS (patients with advanced lung
function impairment), comorbidities (patients with severe
concomitant emphysema), or the mechanism of action of
nintedanib as an angiogenesis inhibitor (patients awaiting
lung transplantation; patients with IPF and lung cancer).
Patients with advanced lung function impairment
Patients with PFTs indicative of advanced lung function
impairment (FVC ≤ 50% or DLCO ≤ 30%) were excluded
from the INPULSIS trials, hence the efficacy of ninteda-
nib in these patients was not established upon the drug’s
approval [2]. The clinical trial INSTAGE examined the
efficacy and safety of nintedanib in combination with
sildenafil, compared with nintedanib and placebo, in
patients with advanced disease defined by DLCO ≤ 35%.
While the trial did not meet its primary endpoint (super-
iority of the combination versus nintedanib alone in the
change from baseline in SGRQ total score), the rate of
FVC decline in patients treated with nintedanib over 24
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weeks aligned with that of patients treated with ninteda-
nib in the INPULSIS trials, whose lung function was less
impaired. No new safety signals were identified in
INSTAGE, and the most common adverse event (AE)
was diarrhoea [11, 64].
While patients entering the INPULSIS trials were
required to have limited lung function impairment, mea-
sured by FVC and DLCO, no such restrictions applied to
patients entering the INPULSIS-ON extension study [6,
65]. Of 731 patients who entered INPULSIS-ON and
had baseline FVC measurements, 41 (5.6%) had FVC ≤
50%, while 690 (94.4%) had FVC > 50%. FVC measure-
ments at week 48 were available in 24 and 558 patients
with FVC ≤ 50% and FVC > 50%, respectively. Relative
and absolute declines in FVC over 48 weeks did not dif-
fer between these groups, and were similar to those ob-
served over 52 weeks in patients treated with nintedanib
in the INPULSIS trials [65]. Taken together, the data
from INSTAGE and INPULSIS-ON suggest that the effi-
cacy of nintedanib extends to patients with more
advanced disease and is similar to that in patients with
less functional impairment, and that nintedanib has a
manageable safety profile irrespective of baseline PFTs
[11, 65]. In the future, trials for particular subgroups of
patients, such as those with more advanced disease,
should be considered.
A single-centre retrospective study of patients with
IPF (N = 186) in Philadelphia, USA, found that patients
who received nintedanib (n = 57) in clinical practice had
lower mean FVC (66%) and DLCO (35%) than those in
the INPULSIS trials (79.8% and 47.4%, respectively); no
new safety signals were observed despite this [66]. In a
single-centre retrospective study in Budapest, Hungary,
patients receiving nintedanib (N = 22) were divided into
two subgroups, one with FVC < 50% (n = 10), and one
with FVC of 50–60% (n = 12). Median survival did not
differ between subgroups (444 and 447 days, respect-
ively). The most common AEs were gastrointestinal and
elevated liver enzymes. The authors noted that patients
with FVC < 50% represented approximately 10% of the
total IPF population of their centre [67]. A recent study
in Japan examined the effects of nintedanib in patients
(N = 22), 8 of whom had advanced lung function impair-
ment (FVC < 50 or DLCO/alveolar volume either <30%
pred or unmeasurable), and found that the most com-
mon AEs in these patients were diarrhoea and elevated
serum aminotransferase levels [68].
Lastly, a single-centre retrospective study in Seoul di-
vided patients (N = 108) with IPF into subgroups of more
advanced (FVC < 50% or DLCO < 30%) and less advanced
(FVC ≥ 50% or DLCO ≥ 30%) lung function impairment at
baseline. Most patients (97.2%) experienced AEs; most fre-
quently diarrhoea (50%) and decreased appetite (45.4%).
No new safety signals were identified. FVC decline with
nintedanib was similar in both subgroups (−1.4% and
−3.5% per year for more and less advanced disease, re-
spectively), and was in turn similar to the rate of decline
observed in the INPULSIS trials (−2.8% and −3.1% for
INPULSIS 1 & 2, respectively) [2, 69].
Patients with concomitant emphysema
Patients with IPF and emphysema typically present with
more preserved FVC than those with isolated IPF [70,
71]. DLCO, conversely, is often lower than in patients
with IPF alone, possibly because of an additive effect of
IPF and emphysema, and the higher frequency of pul-
monary hypertension (PH) associated with IPF and em-
physema [71–73]. In addition to altered PFTs at discrete
timepoints, longitudinal FVC decline appears lower in
patients with emphysema and IPF [70, 71]. Stratification
of patients with IPF and emphysema by extent of emphy-
sema according to HRCT was used to show that patients
with an extent of emphysema of ≥ 15% experienced sig-
nificantly less FVC decline over 48 weeks than those with
an extent of emphysema of < 15%. This finding suggests
that longitudinal FVC decline is not an appropriate
measure of disease progression in patients with IPF and
an extent of emphysema of ≥ 15% [70].
In contrast with other clinical trials, the presence of
emphysema at baseline was not an exclusion criterion in
the INPULSIS trials [2]. A post-hoc analysis of patients
with or without emphysema (assessed by interpretation
of HRCT scans by a single expert radiologist) in the
INPULSIS trials found no significant between-group dif-
ferences in FVC decline, change in SGRQ total score
from baseline, or the risk of first acute exacerbation.
These results suggest that the treatment effect of ninte-
danib is not affected by the presence of emphysema at
baseline [74].
Patients awaiting lung transplantation
Lung transplantation is recommended for the treatment
of IPF in eligible patients [14, 35, 75, 76]. Nintedanib is
an inhibitor of vascular endothelial growth factor
(VEGF), platelet-derived growth factor and fibroblast
growth factor (FGF) pathways [77]. Inhibition of the
VEGF pathway has been associated with an increased
risk of bleeding events [77–81]. VEGF and FGF are
involved in wound healing, and potential disruption of
this process warrants consideration in patients undergo-
ing lung transplantation [80, 82].
Concerns regarding the use of nintedanib in patients
undergoing lung transplantation have not borne out in
clinical practice [83–88]. A single-centre study of pa-
tients in Belgium receiving nintedanib (n = 2) or pirfeni-
done (n = 7) observed no bleeding events or wound
healing impairment for 20–39 days post-operation [89].
In a larger, single-centre retrospective study of patients
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who underwent lung transplantations in Germany (N =
287), 62 patients had IPF, for which 23 were undergoing
treatment with pirfenidone and 7 were undergoing treat-
ment with nintedanib. No significant increases in intra-
operative blood loss, intra- and post-operative use of
blood products, wound healing disorders or anastomotic
complications were observed between patients with IPF
who received nintedanib or pirfenidone and those who
did not [90]. A study of patients with ILD undergoing
bilateral lung transplantation in Vienna, Austria or
Hannover, Germany found that, of 100 patients diag-
nosed with IPF, 23 received pirfenidone and 13 received
nintedanib within 4 weeks prior to surgery. Such use of
nintedanib or pirfenidone was not associated with
increases in bleeding events, impaired wound healing, or
mortality after a median follow-up of 21 months [91].
Patients with IPF and lung cancer
IPF is a risk factor for lung cancer [92–94]. The reported
prevalence of lung cancer in patients with IPF varies
from 3–48%, and it is associated with shorter survival
times than IPF alone [94–96]. Nintedanib, in combin-
ation with docetaxel, is indicated after first-line therapy
for the treatment of non-small-cell lung cancer (NSCLC)
with adenocarcinoma tumour histology [97]. Nintedanib
is known to hinder angiogenesis, which is essential for
tumour growth, metastasis and progression [77, 98].
Nintedanib, therefore, has theoretical potential in the
treatment of lung cancer associated with IPF, although
the most common histotype of lung cancer in IPF is
squamous cell carcinoma, and nintedanib is indicated
for adenocarcinoma [93, 94, 97, 98].
Chemotherapy, surgical procedures and radiotherapy
are all associated with a high risk of acute exacerbations
in patients with IPF and lung cancer. Surgery-related
mortality is increased in patients with IPF and lung cancer,
compared with patients with lung cancer alone [94, 99].
Evidence for the efficacy of nintedanib in patients with
IPF and NSCLC is available from a single case study, in
which a nodule later identified as squamous cell carcin-
oma in a patient with IPF remained stable with ninteda-
nib treatment, but increased in size after discontinuation
[100]. The J-SONIC trial is investigating the efficacy of
nintedanib (compared with no nintedanib) in patients
with NSCLC and IPF who are receiving carboplatin and
nanoparticle albumin-bound paclitaxel [101].
Long-term treatment
The INPULSIS trials showed that nintedanib treatment
slows disease progression in patients with IPF over 52
weeks [2]. IPF is a chronic progressive disease that requires
treatment for longer than 52 weeks, hence extension stud-
ies of the INPULSIS trials (and the Phase II TOMORROW
trial) have been conducted [6, 102].
In the INPULSIS-ON extension study, patients (N =
734), who received either placebo (n = 304) or nintedanib
(n = 430) in INPULSIS, were treated with open-label nin-
tedanib. The mean exposure to nintedanib in INPULSIS-
ON was 31.5 months (range 0.0–56.3); the mean total
exposure in INPULSIS and INPULSIS-ON was 44.7
months (11.9–68.3). No new safety signals were identified,
and the most common AE was diarrhoea. The overall
safety profile of nintedanib over the 4-year INPULSIS-ON
extension study was similar to that established in the earl-
ier 52-week INPULSIS trials [6].
In the INPULSIS trials, more patients in the ninteda-
nib groups reported a "myocardial infarction" event than
in the placebo groups (2.7% vs 1.2%). Conversely, more
patients in the placebo groups reported an "ischaemic
disease" event than in the nintedanib group (3.1% vs
1.7%) [103]. This imbalance in reported myocardial
infarction was not observed in clinical trials of ninteda-
nib in patients with SSc-ILD (SENSCIS) or in patients
with other progressive fibrosing ILDs (INBUILD) [104,
105]. Reported bleeding events in the INPULSIS trials,
including epistaxis and contusion, were higher in ninte-
danib groups than in placebo groups, and serious bleed-
ing events were reported with similar incidence between
groups [88, 103]. Rates of major adverse cardiovascular
events, myocardial infarction and bleeding events in
INPULSIS-ON were similar to or lower than those
observed in the INPULSIS trials, suggesting that contin-
ued nintedanib treatment is not associated with an
increase in the risk of these events [6].
Lung function decline over 192 weeks was assessed as
an exploratory endpoint in INPULSIS-ON. The annual
rate of FVC decline was 135.1 mL, 145.0 mL in patients
who continued nintedanib, and 119.7 mL in patients
who initiated nintedanib in INPULSIS-ON [6]. The an-
nual rate of FVC decline in the INPULSIS trials was
113.6 mL for patients receiving nintedanib, and 223.5
mL for patients receiving placebo [2, 6]. This suggests
that the treatment benefit of nintedanib could extend
beyond 4 years [6].
Use of nintedanib in real-world clinical practice
Nintedanib is currently authorized in over 70 countries
for the treatment of IPF. The estimated cumulative
exposure from first approval in October 2014 through
end of May 2019 is > 80,000 patient-years [106]. The
available real-world data support the safety and efficacy
profiles of nintedanib that were established in clinical
trials [83, 86, 107–111]. Observational studies have
reported declines in FVC of < 5% over 9–11 months in
most patients treated with nintedanib [85, 109, 110].
Diarrhoea remains the most commonly reported AE,
occurring in 33–73% of patients [39, 66, 68, 83–86, 108–
110]. In the INPULSIS trials, 63% of patients who
Valenzuela et al. Respiratory Research            (2020) 21:7 Page 7 of 15
received nintedanib reported diarrhoea, compared with
18% of patients who received placebo [2]. Reported dis-
continuation rates range from 11–45% [39, 66, 84–87,
109, 110]. No new safety signals or increases in bleeding
or cardiovascular events have been reported [39, 66, 83–
87, 91, 108–110].
A 2015 systematic review found that the most common
comorbidities in patients with IPF were PH, obstructive
sleep apnoea, lung cancer, chronic obstructive pulmonary
disease (including emphysema), ischaemic heart disease
(IHD) and gastro-oesophageal reflux disease (GERD) [95].
A real-world study found that lung cancer, arteriosclerosis,
IHD and other cardiovascular diseases were significantly
associated with impaired outcome in patients with IPF
[112]. With the exception of lung cancer, these comorbidi-
ties were also reported in patients in clinical practice who
received nintedanib (Table 2). The presence of comorbidi-
ties at baseline did not appear to affect the safety or efficacy
profile of nintedanib [66, 67, 85, 86, 110]. Similarly, con-
comitant medications at baseline largely had no significant
effects on nintedanib treatment [66, 85, 110].
In two case studies an improvement in FVC was ob-
served after initiation of nintedanib following an acute
exacerbation [114, 115]. There is a lack of real-world
data on post-exacerbation survival in patients treated
with nintedanib or pirfenidone. However, data from the
European IPF Registry (eurIPFreg), the INSIGHTS-IPF
registry (Germany) and the Australian Idiopathic Pul-
monary Fibrosis Registry suggest that patients with IPF
who receive antifibrotic treatment have better overall
survival than patients with IPF who do not receive ninte-
danib or pirfenidone [23, 116, 117]. Post-hoc analyses of
the INPULSIS trials observed an association between
nintedanib treatment and a numerical reduction in mor-
tality following an acute exacerbation [45, 47].
Future directions
Emerging therapeutic strategies
Research into improved treatment options for patients
with IPF continues. Several studies investigated combin-
ation therapy using nintedanib and pirfenidone. A multi-
centre prospective study in Japan (N = 50) observed an
increase in reports of nausea and vomiting when patients
receiving pirfenidone were treated with nintedanib, com-
pared with patients receiving pirfenidone alone [118].
The addition of nintedanib to pirfenidone was not asso-
ciated with any additional safety signals in a prospective
international study of patients (N = 89) on a stable dose
Table 2 Comorbidities and concomitant medication use at baseline in real-world IPF populations receiving nintedanib
Study author, year
[reference]
Galli, 2017 [66] Brunnemer, 2018 [110] Bonella, 2016 [85] Barczi, 2019 [67] Tzouvelekis, 2018 [86] Kreuter, 2017 [113]
Number of patients 57 64 62 22 94 623
Comorbidities, n (%)
Arterial hypertension 28 (43.8) 19 (31) 14 (63.6) 41 (43.6)
PH 11 (19.3) 5 (7.8) 9 (40.9) 16 (17.0)
Congestive heart failure 4 (7)
IHD 14 (24.6) 21 (32.8) 8 (13) ≤5 (22.7)a 20 (21.3)
Diabetes mellitus 15 (26.3) 16 (25) 9 (14.5) 4 (18.2) 18 (19.1)
GERD 31 (54.4) 21 (32.8) 7 (11) 2 (9.1) 38 (40.4) 192 (30.8)
OSA 9 (14.1) 4 (6)
Emphysema 12 (21.1) 9 (14.1) 55 (8.8)
Stroke 2 (3.1)
Concomitant medications, n (%)
Prednisone 10 (17.5)
Anti-acid therapy 37 (64.9) 22 (34.4) (PPI) 16 (26) (PPI)
Anticoagulant 7 (12.3) 7 (10.9) 2 (3)
Aspirin + anticoagulant 3 (4.7)
N-acetyl cysteine 5 (8)
MMF 5 (8.8)
Sildenafil/tadalafil 6 (10.5)
Anti-hypertensive 28 (43.8) 19 (31)
aIncluded under "cardiovascular diseases" in [67], which also included non-IHD, left heart failure, valvular insufficiency
GERD Gastro-oesophageal reflux disease, IHD Ischaemic heart disease, IPF Idiopathic pulmonary fibrosis, MMF Mycophenolate mofetil, OSA Obstructive sleep
apnoea, PH Pulmonary hypertension, PPI Proton pump inhibitor
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of pirfenidone [119]. In the INJOURNEY clinical trial
(N = 104), the addition of pirfenidone to nintedanib
was associated with an increase in gastrointestinal AEs,
compared with nintedanib alone. However, 34 patients
(64%) who received combination therapy completed the
trial, suggesting that combination treatment is feasible in a
large proportion of patients. Exploratory efficacy analysis
suggested that combination therapy reduced FVC decline
to a greater extent than nintedanib alone [8]. A smaller
study (N = 37) observed no pharmacokinetic interactions
between the two drugs [10]. Data from large, prospective
studies are, however, absent.
No safety signals associated with switching from pirfe-
nidone to nintedanib are evident from real-world data
[66, 85, 120]. No difference in efficacy was observed be-
tween patients who initiated nintedanib after discontinu-
ing pirfenidone and those who were pirfenidone-naïve.
A common reason for pirfenidone discontinuation was
disease progression; the efficacy of nintedanib in these
patients suggests that patients who experience disease
progression under pirfenidone could still benefit from
treatment with nintedanib [85, 110]. In a small number
of patients (n = 4) who transitioned from nintedanib to
pirfenidone, no new safety signals were observed [66].
The aforementioned clinical trial INSTAGE assessed
the effect of sildenafil and nintedanib on QoL, compared
with nintedanib alone, in patients with advanced lung
function impairment. While the addition of sildenafil
gave only a numerical improvement in QoL, the results
of this trial suggested that sildenafil might confer add-
itional benefit in lowering the risk of disease progression
in these patients [11]. Furthermore, the benefit of com-
bination therapy on QoL may not have reached the
threshold for significance because the study was under-
powered, as the INSTAGE trial was powered under the
assumption that the effect of sildenafil on QoL would
not be affected by nintedanib therapy. The trial design
did not account for the possibility of a more pronounced
treatment effect of nintedanib on QoL in patients with
lower FVC, as observed in subgroup analyses of the
INPULSIS trials [11, 40]. Future clinical trials in patients
with IPF and a greater degree of lung function impair-
ment should take these potential design limitations into
consideration. The effect of combination therapy was
consistent irrespective of the presence of right heart
dysfunction at baseline [64]. The treatment guidelines
for IPF give a conditional recommendation against
sildenafil for the treatment of IPF, but make no
recommendation regarding the treatment of patients
with PH and IPF [35].
GERD is a common comorbidity in IPF; however, data
on the use of anti-acid therapies are conflicting. While
prespecified analysis of placebo cohorts from the IPFnet
programme suggested positive effects [121], a post-hoc
analysis of data from the placebo arms of the CAP-
ACITY and ASCEND trials suggested that the use of
anti-acid therapies does not affect disease course in pa-
tients with IPF, and international guidelines give a con-
ditional recommendation for these therapies in patients
with IPF and GERD [35, 121, 122]. A post-hoc analysis
of the INPULSIS trials found that use of anti-acid ther-
apies (proton pump inhibitors (PPIs) and histamine-2 re-
ceptor agonists) at baseline did not affect the treatment
benefit of nintedanib [123]. The treatment of GERD with
PPIs might be associated with an increased risk of en-
teric bacterial infection [124], and data suggest that pa-
tients with IPF and FVC < 70% pred who receive anti-
acid therapies are at greater risk of infections (general
and pulmonary) than those who do not [122].
In addition to clinical research using existing therapies,
novel pharmacotherapies are in development [125]. As
nintedanib and pirfenidone are now considered standard
of care in IPF, several trials of novel therapeutics (including
GLPG1690 [126], PRM-151 [127], PBI-4050 [128] and
pamrevlumab [129]) allowed concomitant therapy with
nintedanib or pirfenidone in both treatment and placebo
arms [125–129]. During a Phase II trial of PBI-4050, an in-
hibitor of differentiation of fibroblasts into myofibroblasts,
an apparent interaction with pirfenidone was observed.
Change in mean FVC from baseline to week 12 was nu-
merically superior in the PBI-4050 plus nintedanib group
(+0.06% pred) than in either the PBI-4050 alone (−1.11%)
or the PBI-4050 plus pirfenidone (−2.69%) groups [128].
Future combination regimens will, therefore, be dependent
on the pharmacokinetic and safety profiles of both agents.
Non-pharmacological interventions are also being
explored. A systematic review found that pulmonary
rehabilitation can improve exercise capacity and QoL in
patients with ILD, including IPF, albeit in the short term
[130]. In the SPRINT-IPF trial (NCT03717012), pulmon-
ary rehabilitation in combination with nintedanib will
be tested against nintedanib alone in patients with
IPF (N = 290, planned). The primary endpoint is the
change in 6-minute walk distance [131].
Precision medicine
Despite the relevance of PFTs in the assessment of dis-
ease progression, there is a paucity of biomarkers cap-
able of predicting response to treatment or disease
progression in individual patients [12, 43]. The identifi-
cation of such biomarkers could help address the unmet
need to develop endpoints that more accurately reflect
the degree of fibrogenesis, matrix turnover and func-
tional consequences of fibrosis [12, 132].
Other progressive fibrosing ILDs
Progressive pulmonary fibrosis is the hallmark of IPF,
but this phenotype occurs in other ILDs [13, 133–136].
Valenzuela et al. Respiratory Research            (2020) 21:7 Page 9 of 15
In general, treatment for these diseases involves off-label
use of corticosteroids and immunosuppressive agents
[135]. Due to mechanistic similarities between IPF and
progressive fibrosing ILD, nintedanib therapy is under
investigation in SSc-ILD and in other progressive fibros-
ing ILDs [9, 13, 104].
Systemic sclerosis is a rare autoimmune disease char-
acterized by fibrosis of the skin and internal organs. ILD
is one of the leading causes of morbidity and mortality
in SSc [9, 104, 137]. SSc-ILD has an estimated preva-
lence of 1.7–4.2 per 100,000 individuals in Europe [138].
The SENSCIS trial investigated the use of nintedanib in
patients with SSc-ILD. The primary endpoint was the
annual rate of FVC decline, which was −52.4 mL per
year in patients receiving nintedanib (n = 288) and −93.3
mL per year in patients receiving placebo (n = 288)
[104]. These rates are lower than those in the INPULSIS
trials (−113.6 and −223.5 mL per year in the nintedanib
and placebo arms, respectively), probably because FVC
decline in SSc-ILD follows a more heterogeneous course
than the irreversible progressive decline observed in pa-
tients with IPF [2, 6, 139–141]. Furthermore, the SEN-
SCIS trial included a heterogeneous patient population,
and 48% of patients were receiving continuing treatment
with mycophenolate mofetil [104]. The relative reduc-
tion in FVC decline associated with nintedanib versus
placebo in SENSCIS (44%) was similar to that observed
in the INPULSIS trials (49%) [2, 104]. The AE profile of
nintedanib in patients with SSc-ILD was similar to that
observed in patients with IPF, although a higher propor-
tion of patients reported diarrhoea (76% and 32% in the
nintedanib and placebo arms, respectively) in the SEN-
SCIS trial than in the INPULSIS trials (62% and 18% in
the nintedanib and placebo arms, respectively). poten-
tially arising from the underlying systemic disease [2,
104].
Nintedanib has also been investigated in patients with
ILDs that have developed a progressive fibrosing pheno-
type. The disease in these patients is characterized by
decline in lung function, increasing extent of fibrosis by
HRCT, or worsening of respiratory symptoms, despite
treatment with immunomodulatory therapies [13, 134].
The INBUILD trial assessed the efficacy and safety of
nintedanib in patients with fibrosing ILDs and a progres-
sive phenotype, excluding IPF [13, 142]. The primary
endpoint was the annual rate of FVC decline, which was
−80.8 mL in patients treated with nintedanib (n = 332),
compared with −187.8 mL in patients treated with pla-
cebo (n = 331). Inclusion was based on extent of fibrosis
by HRCT (≥ 10%) and a common underlying progressive
phenotype rather than diagnoses of any particular ILD,
and INBUILD therefore included patients with ILDs
such as: hypersensitivity pneumonitis (n = 173, 26%);
autoimmune-associated ILDs (n = 170, 26%), such as
rheumatoid arthritis-associated ILD (n = 89, 13%) and
SSc-ILD (n = 39, 6%); idiopathic non-specific interstitial
pneumonia (n = 125, 19%); and unclassifiable idiopathic
interstitial pneumonia (n = 114, 17%). Patients were
stratified by the presence or absence of a UIP-like pat-
tern by HRCT. The annual rates of FVC decline in pa-
tients with UIP-like pattern were −82.9 mL and −211.1
mL in patients treated with nintedanib and placebo, re-
spectively. In patients with other HRCT patterns these
were −79.0 mL and −154.2 mL, respectively. The most
common AE was diarrhoea, which occurred in 67% and
25% of patients receiving nintedanib and placebo, re-
spectively. The efficacy of nintedanib in these patients
could suggest common pathobiological mechanisms in
fibrosing ILDs, irrespective of clinical diagnosis [142,
143]. A real-world study of patients (N = 11) with fibros-
ing ILDs that had developed a progressive phenotype who
were treated with either pirfenidone (n = 10) or ninteda-
nib (n = 1) observed that antifibrotic therapy was associ-
ated with stabilization of FVC, further indicating that this
approach might be a valuable treatment option [144].
Conclusion
While the treatment landscape of IPF is growing increas-
ingly favourable, many challenges and unmet needs re-
main. The diagnosis of IPF is still complex, but research
into new techniques that could improve the sensitivity
of diagnosis and reduce the burden of histological proce-
dures is ongoing. Lung function tests are, to date, the
best measure of disease progression and, although pre-
diction of disease progression in individual patients
using PFTs remains problematic, exploration of quantifi-
cation of disease progression and treatment response
using HRCT, digital lung auscultation and blood bio-
markers shows promise. Long-term treatment with nin-
tedanib raised no new safety signals, and suggested that
the treatment benefit extends beyond 4 years. Real-
world evidence has largely corroborated the safety and
efficacy profiles of nintedanib established in clinical tri-
als. The efficacy and safety of nintedanib to treat other
progressive fibrosing ILDs have been examined in clin-
ical trials. Further developments in these areas, and in
the treatment of patients with advanced lung function
impairment, concomitant emphysema and lung cancer
should continue to improve patient outcomes.
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